Chorioamnionitis and Labor Rodney K. Edwards, MD, MS

Obstet Gynecol Clin N Am
32 (2005) 287 – 296
Chorioamnionitis and Labor
Rodney K. Edwards, MD, MS
Department of Obstetrics and Gynecology, Division of Maternal-Fetal Medicine,
University of Florida College of Medicine, PO Box 100294, 1600 Southwest Archer Road,
Gainesville, FL 32610-0294, USA
Chorioamnionitis is a puerperal infection that may be defined clinically or
histologically. It also exists in a subclinical form. This entity may complicate
labor at term and is believed to play a causative role in many cases of spontaneous preterm delivery. Dysfunctional labor, an increased need for cesarean
delivery, and infection-related problems are maternal complications associated
with chorioamnionitis. Appropriate treatment of patients with clinical chorioamnionitis includes delivery and the administration of broad-spectrum antibiotics as soon as possible after diagnosis.
This article focuses primarily on the effects of chorioamnionitis on the
progress of labor and the clinical management of the infection. The epidemiology and pathogenesis of this infection are reviewed. Although the associated maternal and neonatal outcomes are addressed, detailed discussion of
these associations is the subject of other reviews.
Definitions, incidence, and risk factors
The term ‘‘chorioamnionitis,’’ strictly defined, refers to inflammation or infection of the placenta and of the chorion and the amnion (the fetal membranes).
The term may refer to a histologic, subclinical, or clinical diagnosis. Synonyms
for clinical chorioamnionitis include intra-amniotic infection and amnionitis.
Histologic chorioamnionitis is defined by infiltration of the fetal membranes with polymorphonuclear leukocytes, and it occurs far more frequently than
does clinically evident infection [1]. Most cases of histologic chorioamnionitis
E-mail address: [email protected]
0889-8545/05/$ – see front matter D 2005 Elsevier Inc. All rights reserved.
doi:10.1016/j.ogc.2004.12.002
obgyn.theclinics.com
288
edwards
Table 1
Independent risk factors for clinical chorioamnionitis
Risk factor
Nulliparity
Duration of labor
Duration of ROM
Internal fetal monitors
Number of vaginal examinations
Soper et al, [3]
Newton et al, [4]
a
a
a
a
a
a
a
Abbreviation: ROM, rupture of membranes.
a
Independent risk factor by logistic regression analysis.
occur in cases in which there were no clinical signs or symptoms of infection. This
diagnosis can be made in up to 20% of term deliveries and more than 50% of
preterm deliveries.
In contrast, clinical chorioamnionitis occurs in 1% to 2% of term and 5% to
10% of preterm deliveries [2]. The incidence may be higher in the setting
of prolonged rupture of the membranes. Risk factors that often are cited as
being associated with clinical chorioamnionitis include young age, low socioeconomic status, nulliparity, long labor, extended duration of ruptured membranes, multiple vaginal examinations, prolonged internal fetal monitoring,
bacterial vaginosis, colonization with group B streptococci, and meconiumstained amniotic fluid. Table 1 lists the risk factors that were independently
associated with this infection in prospective studies conducted at two tertiary care
medical centers [3,4].
Microbiology and pathogenesis
Most cases of chorioamnionitis are ascending in origin, with organisms
from the vagina gaining access into the upper genital tract through the cervix.
A few cases, however, are caused either by hematogenous spread or invasive
procedures, such as amniocentesis.
The infection is polymicrobial in nature. The organisms most commonly
isolated from the amniotic fluid of patients with clinical chorioamnionitis are
mycoplasmas such as Mycoplasma hominis and Ureaplasma urealyticum,
anaerobic Gram-negative bacilli, such as those of the genera Bacteroides and
Prevotella, coliforms such as Escherichia coli, anaerobic streptococci, and group
B streptococci [5–7]. Table 2 summarizes the results from one study that
evaluated the distribution of microorganisms isolated from the amniotic fluid of
408 patients with chorioamnionitis. Note that in keeping with the contention that
this infection is polymicrobial, the total number of isolates is much larger than
the total number of patients. Supporting ascension from the vagina as the source
of most cases of chorioamnionitis, organisms isolated from subjects in this and
similar studies are found in the bowel flora or in cases of bacterial vaginosis.
289
chorioamnionitis and labor
Table 2
Micro-organisms isolated from 408 patients with chorioamnionitis
Organism
Number of isolates
Patients (%)
Ureaplasma urealyticum
Mycoplasma hominis
Bacteroides bivius
Gardnerella vaginalis
Group B streptococci
Peptostreptococci
Escherichia coli
Fusobacterium species
Enterococci
Other aerobic Gram-negative rods
Bacteroides fragilis
193
125
120
99
60
38
33
23
22
21
14
47
31
29
24
15
9
8
6
5
5
3
Total isolates
748
Data from Sperling RS, Newton E, Gibbs RS. Intra-amniotic infection in low-birth-weight infants.
J Infect Dis 1988;157:113–7.
Chorioamnionitis may result in or occur in conjunction with infection or
inflammation of other gestational tissues. These sites include the decidua
(deciduitis), placental villi (villitis), and the umbilical cord (funisitis). Chorioamnionitis also may result in maternal or fetal bacteremia. In the small percentage of cases that are caused by hematogenous spread, bacteremia actually
may precede and cause the infection of the placenta and fetal membranes. As
stated earlier, however, hematogenously acquired chorioamnionitis is unusual.
Making the diagnosis
Histologic chorioamnionitis occurs with a much higher incidence than clinical chorioamnionitis. Consequently, the occurrence of these two entities correlates poorly [1]. The diagnosis of histologic chorioamnionitis is made based on
identification of polymorphonuclear leukocytes on pathologic examination of
the placenta and fetal membranes. Its diagnosis has little value in the prospective clinical management of patients.
The clinical criteria used to make the diagnosis of clinical chorioamnionitis
include maternal fever, maternal tachycardia, fetal tachycardia, uterine tenderness, and foul-smelling amniotic fluid [2]. Different centers have different
requirements for making this clinical diagnosis. At the University of Florida,
we require a temperature of at least 388C and one or more of the previously
mentioned criteria. Other researchers have published different diagnostic criteria.
Gibbs et al [7], in their prospective studies, defined intra-amniotic infection
on the basis of a temperature of at least 37.88C (1008 F) and two or more of
the following additional criteria: maternal tachycardia, fetal tachycardia, uterine
tenderness, foul odor of the amniotic fluid, and maternal leukocytosis.
290
edwards
Maternal leukocytosis supports—but is not required to make the diagnosis
of—clinical chorioamnionitis. A mild leukocytosis can be associated with labor
or with pregnancy itself; however, a peripheral white blood cell count of more
than 15,000 is suspicious for infection. Leukocytosis particularly is consistent
with infection if a ‘‘left shift’’ (ie, an increase in the proportion of neutrophils,
especially immature forms) is present. One caveat is that the recent
administration of corticosteroids may cause a mild leukocytosis. The increase
will be caused by demarginated mature neutrophils, however, and the presence
of immature forms still would suggest infection.
For cases in which the diagnosis is in doubt or when a diagnosis of subclinical chorioamnionitis is sought, amniocentesis may provide useful information. Tests that commonly are performed on amniotic fluid in an attempt to
diagnose subclinical chorioamnionitis include leukocyte esterase (on a urine
dipstick), glucose, Gram stain, and culture. Of the tests that can be performed
rapidly, amniotic fluid glucose is the one that is the most specific for predicting
a positive amniotic fluid culture [8]. Amniotic fluid interleukin-6 is even more
sensitive and specific [9,10]. The test usually is not available, however, except
in a research setting. Studies that use polymerase chain reaction directed against
the common bacterial ribosomal subunit have demonstrated that amniotic
fluid culture probably is an unsatisfactory ‘‘gold standard’’ for detection of
subclinical chorioamnionitis, because many more patients in preterm labor with
intact membranes have organisms detectable in the amniotic fluid by polymerase chain reaction than by culture [11].
Effects on the progress of labor
In the 1980s, studies were conducted that evaluated the characteristics of
labor in patients with chorioamnionitis. Duff et al [12] evaluated patients who
developed clinical chorioamnionitis after entering labor spontaneously. Seventyfive percent of the patients in that study had decreased uterine contractility, and
despite oxytocin augmentation, 34% required cesarean delivery because of
failure to progress in labor.
As compared with their uninfected counterparts, even patients with subclinical chorioamnionitis seem to have poorer uterine contractility. Silver et al
[13] found that patients with positive amniotic fluid cultures but no clinical
signs or symptoms of infection required higher doses of oxytocin to achieve
adequate uterine activity. Many patients with chorioamnionitis, perhaps as
many as 75%, require oxytocin augmentation [3,12]. When this diagnosis is
made, dysfunctional labor and the need for oxytocin augmentation should
be anticipated.
Whether chorioamnionitis is a result of or results in protracted labor is a
difficult question. At least one study suggested that the former is true, however.
Satin et al [14] conducted a case-control study that demonstrated that patients
with chorioamnionitis diagnosed before oxytocin augmentation had shorter
chorioamnionitis and labor
291
intervals from initiation of oxytocin to delivery than did uninfected controls.
The cesarean delivery rate was not increased in that infected subgroup. In
contrast, when chorioamnionitis was diagnosed after oxytocin augmentation had
begun, the interval from oxytocin initiation until delivery was significantly
longer than in the uninfected controls, and the cesarean delivery rate was
increased by a factor of 4 (40% versus 10%; P b 0.001).
Mark et al [15] conducted a cohort study to evaluate the relationship between
clinical chorioamnionitis and abnormal uterine function, including labor abnormalities, cesarean delivery, and postpartum hemorrhage. In their study, as in the
others cited previously, chorioamnionitis was associated with an increased
likelihood of labor abnormalities and cesarean delivery. After multivariate
analysis, the chorioamnionitis group was 50% (95% confidence interval 20, 80)
more likely to have a postpartum hemorrhage after cesarean and 80% (95% confidence interval 50, 110) more likely to have a postpartum hemorrhage after vaginal delivery. When making the diagnosis of clinical chorioamnionitis, a clinician
should anticipate suboptimal uterine contractility before and after delivery.
Many cases of preterm labor, particularly if remote from term, are related
to infection or inflammation. Clinically evident or subclinical chorioamnionitis
is the most frequent identifiable cause of preterm labor. Preterm labor may have
a different mechanism than labor at term. In myometrial cell culture, prolonged
exposure to interleukin-1 has been shown to decrease the production of inositol
triphosphate by myometrial cell and to decrease intracellular calcium [16]. The
number of oxytocin receptors on the surface of the myometrial cells is decreased
by a factor of 10 with such prolonged pro-inflammatory stimulation [17]. In the
setting of chorioamnionitis, labor probably is not as much associated with
oxytocin as it is with prostaglandins produced by cyclo-oxygenase-2 in response
to the pro-inflammatory stimulus. The results of these basic science experiments also may explain partially the increased rate of labor abnormalities that
are encountered in the setting of chorioamnionitis.
Management
For the most part, the management of patients with clinical chorioamnionitis
centers on effecting delivery and administering broad-spectrum antibiotics.
Although there does not seem to be a need for an arbitrary time limit from
diagnosis to delivery [18], as discussed in the previous section, the rate of
cesarean delivery increases in patients with this infection.
The most widely studied regimen for the treatment of chorioamnionitis is the
combination of gentamicin (Garamycin), 1.5 mg/kg intravenously every 8 hours,
plus either ampicillin (Omnipen; Principen), 2 g intravenously every 6 hours,
or aqueous penicillin G, 5 million U intravenously every 6 hours [19,20]. A
drug to provide enhanced coverage of anaerobic bacteria should be added for
patients who undergo cesarean delivery. Appropriate choices include clinda-
292
edwards
mycin (Cleocin) or metronidazole (Flagyl). In some clinical settings, singleagent treatments may be more cost effective or more desirable because of other
considerations. Reasonable choices include extended-spectrum penicillins or
cephalosporins, such piperacillin-tazobactam (Zosyn) or cefotetan (Cefotan) [19].
Antibiotic therapy should be initiated as soon as possible after the diagnosis
of chorioamnionitis is made. In the past, there was concern about such an
approach resulting in false-negative neonatal blood cultures that would
complicate decision making in the care of the neonate. The available evidence
clearly shows an advantage of intrapartum treatment over immediate postpartum
treatment of chorioamnionitis, however.
In 1987, Sperling et al [21] published a cohort study that evaluated
257 mother-infant pairs. Intrapartum or postpartum treatment was left to the
discretion of the treating physician. As would be expected, the group that
received intrapartum treatment had a longer diagnosis to delivery interval
(4.7 versus 1.9 hours; P b 0.001). The rate of neonatal sepsis was significantly
lower in that group (2.8 versus 19.6%; P b 0.001), however, and there was a
trend toward a lower rate of sepsis-related neonatal mortality (0.9 versus 4.3%;
P = 0.15). The following year, Gilstrap et al [22] published a similar retrospective study of 312 women with chorioamnionitis. They demonstrated a lower
rate of neonatal bacteremia in the group that received antibiotics intrapartum
rather than immediately postpartum (1.5 versus 5.7%; P = 0.06).
Finally, Gibbs et al [23] conducted a randomized, nonblinded trial of intrapartum compared with immediate postpartum treatment of chorioamnionitis.
They used a combination of ampicillin plus gentamicin, and they added clindamycin to the regimen for patients who underwent cesarean delivery. The results
of the study were so dramatic that the trial was halted prematurely by its data
safety monitoring board after enrollment of only 45 patients because of ethical
issues of withholding treatment of future enrollees who would be randomized to
the postpartum treatment group. There were no cases of neonatal sepsis in the
intrapartum treatment group, compared with a rate of 21% in the postpartum
treatment group (P = 0.03). The maximum maternal temperature in the postpartum period also was lower with intrapartum treatment.
Based on the results of these three studies, it seems clear that treatment
for chorioamnionitis should be started intrapartum as soon as possible after the
diagnosis of chorioamnionitis is made. Such an approach results in decreased
rates of neonatal infection and improved maternal outcome and is not associated
with any increase in delayed neonatal sepsis.
The duration of maternal antibiotic therapy necessary in the postpartum
period for women who were diagnosed with chorioamnionitis intrapartum traditionally has been thought to be 48 to 72 hours [19,24]. This recommendation
primarily was based on expert opinion (level III evidence), however, and recent
investigators have challenged the need for prolonged antibiotic therapy in the
postpartum period.
Chapman and Owen [25] conducted a randomized clinical trial that involved
women with chorioamnionitis who delivered vaginally. During labor, women
chorioamnionitis and labor
293
received a combination of ampicillin and gentamicin. At the time of delivery,
subjects were randomized to receive either a single 2-g dose of cefotetan or
this same dose every 12 hours for 48 hours. The study was not powered to
detect a difference in treatment failure between groups. In the single and multiple dose groups, respectively, the treatment failure rate was 11% compared with
3.7% (P = 0.27). The single-dose regimen was associated with shorter mean
maternal postpartum hospital stays, however (33 versus 57 hours; P b 0.001).
Turnquest et al [26] published a randomized clinical trial that involved
women with chorioamnionitis who underwent cesarean delivery. All patients
received intrapartum ampicillin. Preoperatively, they received doses of gentamicin plus clindamycin. Postpartum, patients were randomized to receive no
additional antibiotics or gentamicin and clindamycin every 8 hours for 24 hours.
Although this study also was underpowered to detect a difference in treatment
failure rate between groups, the rates were 14.8% and 21.8% for the no antibiotics and the antibiotics groups, respectively.
To address this issue more definitively, we conducted a randomized clinical
trial of an abbreviated postpartum antibiotic regimen for patients with chorioamnionitis that was sufficiently powered to address treatment failure as the
primary outcome [27]. Women with vaginal and cesarean deliveries were included. The intrapartum treatment regimen was ampicillin and gentamicin.
Patients who delivered vaginally received either the next scheduled dose of both
drugs or continued ampicillin and gentamicin until afebrile and asymptomatic
for at least 24 hours postpartum. Patients who underwent cesarean delivery
received a dose of clindamycin at the time of umbilical cord clamping. Patients
who were randomized to the abbreviated treatment regimen received no
additional doses of clindamycin but did receive the next scheduled dose each
of ampicillin and gentamicin. The other group of subjects received all three
drugs until afebrile and asymptomatic for at least 24 hours postpartum. We
defined treatment failure as one postpartum temperature at or above 398C or two
temperatures, at least 4 hours apart, of at least 38.48C. For the short and long
course groups, respectively, the rates of treatment failure were 4.6% compared
with 3.5% (P = 0.64). Infection-related complications were rare and did not
differ between groups. A short course of antibiotics seems to be sufficient
postpartum therapy for women with chorioamnionitis.
Maternal and neonatal outcomes
Maternal bacteremia is an uncommon complication of clinical chorioamnionitis and occurs in less than 10% of cases [20]. Because bacteremia is infrequent and the infection is treated with broad-spectrum antibiotics, performing
blood cultures is not necessary in the routine care of patients with chorioamnionitis. Operations performed in an infected surgical field (eg, cesarean
delivery of a patient with clinical chorioamnionitis) are associated with an increased likelihood of complications. Fortunately, however, wound infections oc-
294
edwards
cur in fewer than 10% of cases, and pelvic abscess is rare with the use of
perioperative anti-anaerobic antibiotics [27].
It is well established that there are increased rates of bacteremia, clinical
sepsis, and mortality in infants born to women with chorioamnionitis. The rates
of these complications decrease significantly with the prompt administration of
maternal antibiotics intrapartum. Other neonatal complications associated with
chorioamnionitis have been appreciated more recently, however.
Grether and Nelson [28] published a case-control study of infants with birth
weights of at least 2500 g. Clinical chorioamnionitis was associated with an
odds ratio of 9.3 for cerebral palsy. Infection also was linked to low Apgar
scores, hypotension, the need for resuscitation at the time of delivery, and
neonatal seizures. Another group of investigators reported that in a cohort of
infants with birth weights between 500 and 1500 g, after adjusting for other
factors, clinical chorioamnionitis was associated with a threefold increased risk
of intraventricular hemorrhage, periventricular leukomalacia, and seizures within
the first 24 hours of birth [29]. Periventricular leukomalacia is the radiographic
finding most closely linked to the later development of cerebral palsy.
Evidence exists that this association between chorioamnionitis and adverse
neurologic outcome in the neonate is caused by the inflammatory response. In a
cohort of women with preterm labor but without the clinical diagnosis of
chorioamnionitis, Yoon et al [30] found that increased amniotic fluid levels of
pro-inflammatory cytokines (tumor necrosis factor-alpha, interleukin-1beta, and
interleukin-6) were associated with a four- to sixfold increased risk of cystic
periventricular leukomalacia. The same group reported that the presence of
funisitis or increased amniotic fluid levels of interleukin-6 and interleukin-8 all
had adjusted odds ratios of 5 to 7 for the clinical diagnosis of cerebral palsy in
the child at the age of 3 years [31].
Summary
Clinical chorioamnionitis occurs in 1% to 2% of term and up to 15% of
preterm deliveries. The incidence of histologic chorioamnionitis is much higher
than that of clinically diagnosed infection, and the correlation between these
entities is poor. Most cases of chorioamnionitis are caused by organisms
ascending into the uterus from the lower genital tract. The pathogens involved
in this polymicrobial bacterial infection primarily are mycoplasmas, anaerobes,
coliforms, and group B streptococci.
The infection primarily is diagnosed clinically. In selected situations, however, amniocentesis may be useful in uncovering subclinical cases of chorioamnionitis. When chorioamnionitis is diagnosed, dysfunctional labor and the
need for oxytocin augmentation should be anticipated. Broad-spectrum antibiotics should be started at the time of diagnosis; such an approach improves
maternal and neonatal outcome. Anti-anaerobic coverage is needed after ce-
chorioamnionitis and labor
295
sarean delivery, but a short course of antibiotics is sufficient for postpartum
treatment of patients with chorioamnionitis.
Despite appropriate therapy, recent evidence has demonstrated that even
subclinical chorioamnionitis is associated with neonatal complications. These
complications include not only infection but also intraventricular hemorrhage,
periventricular leukomalacia, and the development of cerebral palsy.
References
[1] Van Hoeven KH, Anyaegbunam A, Hochster H, et al. Clinical significance of increasing
histologic severity of acute inflammation in the fetal membranes and umbilical cord. Pediatr
Pathol Lab Med 1996;16:731 – 44.
[2] Gibbs RS, Duff P. Progress in pathogenesis and management of clinical intraamniotic
infection. Am J Obstet Gynecol 1991;164:1317 – 26.
[3] Soper DE, Mayhall CG, Dalton HP. Risk factors for intraamniotic infection: a prospective
epidemiologic study. Am J Obstet Gynecol 1989;161:562 – 8.
[4] Newton ER, Prihoda TJ, Gibbs RS. Logistic regression analysis of risk factors for intraamniotic infection. Obstet Gynecol 1989;73:571 – 5.
[5] Sperling RS, Newton E, Gibbs RS. Intra-amniotic infection in low-birth-weight infants. J Infect
Dis 1988;157:113 – 7.
[6] Romero R, Sirtori M, Oyarzun E, et al. Infection and labor. V. Prevalence, microbiology, and
clinical significance of intraamniotic infection in women with preterm labor and intact membranes. Am J Obstet Gynecol 1989;161:817 – 24.
[7] Gibbs RS, Blanco JD, St. Clair PJ, et al. Quantitative bacteriology of amniotic fluid from
women with clinical intraamniotic infection at term. J Infect Dis 1982;145:1 – 8.
[8] Greig PC, Ernest JM, Teot L. Low amniotic fluid glucose levels are a specific but not
a sensitive marker for subclinical intrauterine infections in patients in preterm labor with intact
membranes. Am J Obstet Gynecol 1994;171:365 – 71.
[9] Kara M, Ozden S, Arioglu P, et al. The significance of amniotic fluid interleukin-6 levels
in preterm labour. Aust N Z J Obstet Gynaecol 1998;38:403 – 6.
[10] El-Bastawissi AY, Williams MA, Riley DE, et al. Amniotic fluid interleukin-6 and preterm
delivery: a review. Obstet Gynecol 2000;95:1056 – 64.
[11] Hitti J, Riley DE, Krohn MA, et al. Broad-spectrum bacterial rDNA polymerase chain reaction
assay for detecting amniotic fluid infection among women in premature labor. Clin Infect Dis
1997;24:1228 – 32.
[12] Duff P, Sanders R, Gibbs RS. The course of labor in term patients with chorioamnionitis.
Am J Obstet Gynecol 1983;147:391 – 5.
[13] Silver RS, Gibbs RS, Castillo M. Effect of amniotic fluid bacteria on the course of labor
in nulliparous women at term. Obstet Gynecol 1986;68:587 – 92.
[14] Satin AJ, Maberry MC, Leveno KJ, et al. Chorioamnionitis: a harbinger of dystocia. Obstet
Gynecol 1992;79:913 – 5.
[15] Mark SP, Croughan-Minihane MS, Kilpatrick SJ. Chorioamnionitis and uterine function.
Obstet Gynecol 2000;95:909 – 12.
[16] Rauk PN, Chiao JP. Oxytocin signaling in human myometrium is impaired by prolonged
exposure to interleukin-1. Biol Reprod 2000;63:846 – 50.
[17] Rauk PN, Friebe-Hoffman U. Interleukin-1b down regulates the oxytocin receptor in cultured
uterine smooth muscle cells. Am J Reprod Immunol 2000;43:83 – 9.
[18] Hauth JC, Gilstrap III LC, Hankins GD, et al. Term maternal and neonatal complications
of acute chorioamnionitis. Obstet Gynecol 1985;66:59 – 62.
[19] Duff P. Antibiotic selection for infections in obstetric patients. Semin Perinatol 1993;17:
367 – 78.
296
edwards
[20] Newton ER. Chorioamnionitis and intraamniotic infection. Clin Obstet Gynecol 1993;36:
795 – 808.
[21] Sperling RS, Ramamurthy RS, Gibbs RS. A comparison of intrapartum versus immediate
postpartum treatment of intraamniotic infection. Obstet Gynecol 1987;70:861 – 5.
[22] Gilstrap LC, Leveno KJ, Cox SM, et al. Intrapartum treatment of acute chorioamnionitis:
impact on neonatal sepsis. Am J Obstet Gynecol 1988;159:579 – 83.
[23] Gibbs RS, Dinsmoor MJ, Newton ER, et al. A randomized trial of intrapartum versus
postpartum treatment of women with intraamniotic infection. Obstet Gynecol 1988;72:823 – 8.
[24] Gilstrap LC, Cox SM. Acute chorioamnionitis. Obstet Gynecol Clin N Am 1989;16:373 – 9.
[25] Chapman SJ, Owen J. Randomized trial of single-dose versus multiple-dose cefotetan for
the postpartum treatment of intrapartum chorioamnionitis. Am J Obstet Gynecol 1997;177:
831 – 4.
[26] Turnquest MA, How HY, Cook CR, et al. Chorioamnionitis: is continuation of antibiotic
therapy necessary after cesarean section? Am J Obstet Gynecol 1998;179:1261 – 6.
[27] Edwards RK, Duff P. Single additional dose postpartum therapy for women with chorioamnionitis. Obstet Gynecol 2003;102:957 – 61.
[28] Grether JK, Nelson KB. Maternal infection and cerebral palsy in infants of normal birth
weight. JAMA 1997;278:207 – 11.
[29] Alexander JM, Gilstrap LC, Cox SM, et al. Clinical chorioamnionitis and the prognosis
for very low birth weight infants. Obstet Gynecol 1998;91:725 – 9.
[30] Yoon BH, Jun JK, Romero R, et al. Amniotic fluid inflammatory cytokines (interleukin-6,
interleukin-1beta, and tumor necrosis factor-alpha), neonatal brain white matter lesions,
and cerebral palsy. Am J Obstet Gynecol 1997;177:19 – 26.
[31] Yoon BH, Romero R, Park JS, et al. Fetal exposure to an intra-amniotic inflammation
and the development of cerebral palsy at the age of three years. Am J Obstet Gynecol 2000;
182:675 – 81.